Perimenopause Treatment: What Actually Helps With Hot Flashes, Sleep, Mood, and Brain Fog

Start with the foundation: lifestyle medicine

Before — and alongside — any medication, lifestyle medicine is the base layer of perimenopause treatment. Not because sleep, food, movement, and stress skills are "natural fixes," but because this transition is a real physiologic stress test: hormones fluctuate, sleep becomes easier to disrupt, hot flashes can fragment recovery, mood can become more reactive, and cardiometabolic risk can start shifting in the background. A recent lifestyle-medicine review frames perimenopause as a window when daily habits can reduce symptom burden and lower long-term chronic-disease risk — noting that "evidence-based lifestyle interventions can mitigate menopausal symptoms and reduce risk of chronic disease across the lifespan." (Perimenopause and Lifestyle Medicine, 2026)

The review organizes this around the same body systems you feel day to day — it describes "five lifestyle medicine pillars (nutrition, physical activity, social connection, sleep, stress management)." (Perimenopause and Lifestyle Medicine, 2026)

In practice, that means building a routine that does several jobs at once. Regular movement — ideally a mix of aerobic work and strength or resistance training — supports heart health, insulin sensitivity, muscle, bone, and body composition at a time when visceral fat and cardiovascular risk can become more important. A nutrient-dense, plant-forward pattern helps stabilize energy and supports cardiometabolic health. Protecting sleep matters because hot flashes, night sweats, anxiety, and nighttime waking can feed each other: worse sleep can make the next day feel more emotionally and physically volatile. Stress management is not "just relax"; it is training your nervous system to come down from repeated surges of heat, adrenaline, rumination, and poor recovery. For the broader lifestyle map, see our [perimenopause guide](/perimenopause/general). (womenshealth.gov)

Lifestyle can help meaningfully, but it is not a moral test and it rarely "cures" perimenopause symptoms by itself. The evidence for lifestyle approaches is strongest as a foundation and as an add-on: useful for many people, variable for vasomotor symptoms like hot flashes and night sweats, and not a replacement for medical care when symptoms are severe, sleep is collapsing, mood feels unsafe, bleeding changes are concerning, or daily functioning is shrinking. (review, PMC)

Medication family A: menopausal hormone therapy (MHT / HRT)

MHT — also called HRT — is still the strongest medical option for many people whose perimenopause is being driven by vasomotor symptoms: hot flashes, night sweats, sleep broken by heat surges, and the downstream fatigue that follows. NICE recommends offering HRT for vasomotor symptoms associated with menopause, but the key word is offering, not self-starting. This is a clinician-guided decision: your age, where you are in the transition, how disruptive your symptoms are, whether you still need contraception, your uterus status, your migraine/clot/cardiovascular/breast-cancer history, and your preferences all change the plan. (NICE NG23)

⚠️ Clinician-directed — no self-dosing; doses deliberately omitted. A reviewed cardiovascular-risk paper puts it plainly: "A personalized assessment when initiating MHT should consider age, time since menopause, baseline cardiovascular (CV) risk, and choice of MHT formulation." (CV risk & MHT review, PMC)

Formulation matters because your body does not "see" every hormone plan the same way. Oral and transdermal routes, estrogen-only and combined therapy, different estrogen/progestogen types, and sequential versus continuous approaches can carry different benefit–risk profiles. NICE explicitly says the HRT discussion should cover those differences and be tailored to your individual circumstances and risk factors; a clinician decides the medication choice and dose. (NICE NG23) The same review notes that "contemporary formulations such as low-dose transdermal estrogen and micronized progesterone have lower cardiovascular risk." (CV risk & MHT review, PMC)

On the long-term-safety worry: the right frame is not "MHT is safe for everyone." It is "risk depends on the person, timing, formulation, and medical history." A nationwide Danish registry study found no increase in all-cause mortality overall among MHT users in that cohort, reporting "an adjusted hazard ratio of 0.96 (95% confidence interval (CI) 0.93 to 0.98)" for past or present use — but that finding does not erase contraindications or individual risks, and an observational cohort association is not a personal safety guarantee. (nationwide mortality cohort, PMC)

So if you have a history of breast cancer or high breast-cancer risk, venous thromboembolism risk, coronary heart disease, stroke, liver disease, unexplained bleeding, or another condition that could be affected by hormones, this is not a "pick a product online" situation. NICE advises specialist input when symptoms coexist with HRT contraindications or when the best option is uncertain, and it specifically calls out extra care for people at increased VTE risk and those with personal histories of coronary heart disease, stroke, or breast-cancer risk. (NICE NG23)

Perimenopause-specific note: if you are still having periods — even irregularly — the plan has to do two jobs at once. It has to treat symptoms, but it may also need to account for bleeding pattern, cycle control, and contraception. NICE identifies perimenopause in people 45+ by recently started vasomotor symptoms plus menstrual-cycle change, and it notes that hormonal treatments can make menopause harder to identify because bleeding and hormone markers may be altered. That is one reason your clinician may ask about your exact bleeding pattern, pregnancy risk, current contraception, and whether you need symptom treatment, contraception, or both. (NICE NG23)

For background on what symptoms may be part of this picture, see [perimenopause symptoms](/perimenopause/symptoms). If you are not sure whether you are in perimenopause, menopause, or something else that mimics it, start with [perimenopause diagnosis](/perimenopause/diagnostic).

Medication family B: non-hormonal options

For people who can't use menopausal hormone therapy, don't want hormones, or are mainly struggling with mood, anxiety, sleep disruption, and hot flashes, non-hormonal options can be part of perimenopause treatment. The important part is matching the medicine to the symptom pattern: what feels like "perimenopause" in your body may be vasomotor instability, a primary anxiety disorder, poor sleep feeding panic-like sensations, depression, or several of these at once. Doses, combinations, and monitoring are set by a clinician.

⚠️ Clinician-directed only — no self-dosing; the medicines below are named at the class level, without doses.

Certain antidepressants (SSRIs/SNRIs) for hot flashes and mood. Some SSRIs and SNRIs are used when hot flashes overlap with low mood or anxiety, because these medicines can act on the same brain chemicals involved in temperature regulation and emotional arousal. They are not "one-size-fits-all": the clinician looks at your mental-health history, sleep, sexual side effects, other medicines, blood pressure or heart rhythm concerns, and whether hot flashes or mood symptoms are the main target. Trials and reviews support selected SSRIs/SNRIs for reducing menopausal vasomotor symptoms, and perimenopausal-depression guidance lists antidepressants and psychotherapy as front-line options for clinical depression in this window. One review notes that "escitalopram and venlafaxine effectively manage depressive symptoms and vasomotor instability in patients with major depressive disorder." (SSRI/SNRI review, PubMed; FIGO 2026 recommendations)

Anxiety in perimenopause. Anxiety and low mood are common in this window, which is why the anxiety-treatment question comes up so often — the same review observes that "symptoms of anxiety and depression are prevalent during the perimenopause." (FIGO 2026 recommendations)

Treatment for perimenopausal anxiety is individualized because the same "wired, unsafe, can't settle" feeling can come from different body loops: estrogen fluctuation affecting sleep and thermoregulation, night sweats causing repeated awakenings, a new or recurrent anxiety disorder, depression with agitation, thyroid or cardiac issues, or stress load finally outrunning recovery. A clinician may combine lifestyle work, sleep stabilization, CBT or menopause-specific CBT, and — when symptoms meet criteria or are not settling — medication or hormone therapy when appropriate. NICE specifically includes CBT as an option for low mood and anxiety linked with menopause, while perimenopausal-depression guidance emphasizes assessing menopausal stage, co-occurring vasomotor and sleep symptoms, psychosocial factors, and psychiatric history before choosing antidepressants, psychotherapy, hormone therapy, or a combination. (NICE NG23)

A newer non-hormonal class for hot flashes (NK-receptor antagonists). Hot flashes are not just "heat"; they start in the brain's temperature-control network, where falling and fluctuating estrogen can narrow the body's comfort zone. Neurokinin-receptor antagonists target that pathway directly rather than adding estrogen. FDA-approved prescription examples now include an NK3-receptor antagonist and a dual NK1/NK3-receptor antagonist for moderate-to-severe vasomotor symptoms due to menopause; the evidence base is mainly from menopausal and postmenopausal VMS trials, so in perimenopause this is a clinician-prescribed discussion, not an OTC experiment. A 2026 review describes how "neurokinin (NK) receptor antagonists resemble a novel, promising generation of medications that provide fewer adverse events compared to hormonal therapy." (FDA approval, fezolinetant; NK-antagonist review)

Gabapentin and other adjuncts. Gabapentin is sometimes used off-label for hot flashes, especially when night sweats are breaking sleep and the next day feels like anxiety, brain fog, and zero resilience. It is not a hormone and it is not a "sleep supplement"; it is a prescription medication a clinician weighs against side effects such as dizziness, unsteadiness, or drowsiness, your fall risk, other sedating medicines, and whether the main goal is fewer night-time vasomotor symptoms. Randomized trials in menopausal and postmenopausal women found gabapentin improved hot-flash measures compared with placebo, but the fit depends on the person. (gabapentin RCT, PubMed)

Over-the-counter and supplements. OTC products are appealing because they feel lower-stakes: soy isoflavones, red clover, black cohosh, flaxseed, "menopause blends," magnesium stacks, adaptogens. The honest read is less exciting. NCCIH summarizes the evidence for many natural products as limited, inconsistent, or small in effect; Cochrane reviews on phytoestrogens and black cohosh do not support treating supplements like reliable hot-flash therapy for everyone. "Natural" also does not mean inert: supplements can interact with medicines, act like hormones in some contexts, vary by product quality, or create liver-safety concerns in rare cases, especially with black cohosh products. If you have a history of breast cancer, liver disease, blood clots, complex medication use, heavy bleeding, or you are considering combining several products, bring the exact labels to your clinician or pharmacist before starting. (NCCIH)

Sleep: cognitive behavioral therapy (CBT)

Sleep is one of the first things to break in perimenopause. Partly because night sweats keep waking your brain up. Partly because the hormonal shift can make the whole sleep system more reactive: you fall asleep tired, but your body keeps surfacing, checking, heating, cooling, worrying. That is why CBT for insomnia — especially menopause-specific CBT or CBT-I adapted for hot flashes and night wakings — is more than "sleep hygiene." It works on the loop that keeps insomnia alive: time awake in bed, conditioned alertness, anxious sleep thoughts, irregular sleep pressure, and the way vasomotor symptoms start to feel threatening at night. NICE now recommends considering menopause-specific CBT for sleep problems such as night-time awakening when they happen with vasomotor symptoms; broader sleep guidelines also place multicomponent CBT-I as a first-line behavioral approach for chronic insomnia. (NICE NG23)

The direct menopause-specific trial evidence is promising, not final. A 2026 pilot RCT randomized 43 peri- and postmenopausal women with insomnia disorder and at least one nocturnal hot flash per night to CBT-MI or menopause education control. (CBT for menopausal insomnia pilot RCT, PubMed) It reported that "CBT-MI compared with MEC significantly reduced ISI" (the Insomnia Severity Index).

Just as important: the intervention was built for the two-part problem — insomnia plus the hot-flash disruption behind it, not sleep in isolation. The authors concluded that "a CBT intervention targeting both insomnia and VMS showed promising improvements in sleep and hot flash interference in midlife women." (CBT for menopausal insomnia pilot RCT, PubMed)

Read that as promising evidence, not a settled cure. The pilot was small. But it sits inside a wider signal: in the MsFLASH randomized trial, 106 peri- and postmenopausal women with moderate insomnia symptoms and hot flashes received telephone CBT-I or menopause education; CBT-I produced larger improvements in insomnia severity and sleep quality, with differences sustained at 24 weeks. A newer systematic review and meta-analysis of RCTs in menopausal women also found CBT-I was associated with better sleep quality and lower insomnia severity across face-to-face, telephone, and internet formats. (MsFLASH CBT-I trial, PubMed)

Welltory angle. Because so much perimenopausal sleep loss is driven by nocturnal symptoms, your [sleep](/sleep) and overnight [HRV](/hrv) trends can help separate "I feel awful this morning" from "my night was objectively fragmented." Sleep-stage estimates and overnight HRV patterns can show which nights look disrupted and whether a tactic — CBT, cooling the room, changing evening activity, protecting a fixed wake time — is moving the needle. They are not a sleep-lab diagnosis: consumer wearables are generally better at estimating sleep/wake timing than precise sleep stages, and they vary by device. Welltory tracks this context for you and your clinician; it does not diagnose perimenopause or any condition. But for day-to-day pattern tracking, it can make the invisible part of perimenopause easier to see. (wearable sleep-tracking review, PubMed)

The umbrella principle: individualized, layered care

The through-line is simple, but it matters: no two perimenopause plans are identical. Your symptoms, cycle pattern, health history, migraine pattern, clotting risk, blood pressure, sleep, mood, work stress, family history, and what you actually want from treatment all change the plan. FIGO's 2026 recommendations frame care this way: layered, symptom-led, and individualized rather than one-size-fits-all — stating that "treatment should be individualized and may include lifestyle changes, cognitive-behavioral therapy, and hormone therapy." (FIGO 2026 recommendations, PubMed)

For mood specifically, the delivery route of hormones can matter. The same recommendations note that "transdermal estradiol is preferred for managing mood swings, particularly in women with metabolic risks" — a clinician-level formulation choice, not a self-start instruction.

And non-drug approaches are part of the toolkit, not an afterthought. They work through your nervous system, not through willpower: steadier sleep lowers threat sensitivity; movement improves insulin sensitivity and stress chemistry; therapy and mindfulness can reduce the loop where hot flashes, poor sleep, anxiety, and body vigilance keep feeding each other. FIGO includes lifestyle changes, therapy, mindfulness, and exercise in the care model for menopausal mental health, noting that "non-pharmacological interventions, such as lifestyle changes, therapy, mindfulness, and exercise have shown benefits." (FIGO 2026 recommendations, PubMed)

Symptom-targeted notes: Weight gain and body-composition changes are not just about eating more or "losing discipline." During the menopause transition, fat mass can rise, lean mass can fall, and abdominal/visceral fat can become more prominent; aging, lower activity, sleep disruption, and ovarian hormone changes all pull on the same metabolic system. The useful first layer is boring because it is foundational: resistance training, aerobic movement, protein-forward nutrition, and sleep protection. (body-composition review, PMC)

Hormone therapy is not a weight-loss treatment. Cochrane data found no evidence that estrogen-based hormone therapy adds extra menopause-related weight gain, but that is different from saying it should be used as a weight-control plan. (Cochrane HRT & weight review, PubMed)

Brain fog, memory slips, and concentration problems are also real. For many people they show up as word-finding trouble, poor working memory, slower processing, or a feeling that the brain will not "catch" the way it used to. Reviews link these complaints with perimenopause itself, but also with sleep problems, vasomotor symptoms, depression, anxiety, and stress load — which is why treating night sweats, insomnia, mood symptoms, thyroid issues, anemia, medication effects, and burnout can all matter. If the change is sudden, progressive, unsafe, or unlike you, it deserves a clinician's evaluation rather than being written off as hormones. (cognition review, PMC)

Heart palpitations can happen around perimenopause, but the important move is not to assume. A pounding, fluttering, skipping, or racing heartbeat can come from stress, anxiety, caffeine, electrolyte shifts, thyroid problems, anemia, medications, or an arrhythmia. Get palpitations checked by a clinician when they last, change from your baseline, or affect your quality of life — and seek immediate emergency medical care if they come with chest pain, fainting, severe shortness of breath, or the feeling that you might pass out. (American Heart Association)

ADHD-type attention symptoms are a frequent search because perimenopause can make old coping systems fail: less sleep, more anxiety, more brain fog, and more hormonal variability can all make focus feel worse. But this is not a self-treatment area. The evidence on stimulant and non-stimulant ADHD medication specifically in peri/menopausal women is still limited, and a recent review found no randomized controlled trials specific to this population. That makes it a clinician conversation: clarify whether this is ADHD, sleep deprivation, anxiety, depression, medication side effects, thyroid disease, iron deficiency, or a mix — then treat the right target. (review, PMC)

Why symptoms are worth treating (not "just push through")

Hot flashes were long treated as benign, but "benign" can be a misleading word when your sleep, focus, mood, workday, and sense of control are getting hit. In a multicenter cross-sectional study of 3,523 women aged 40–60, greater hot-flash severity tracked with lower health-related quality-of-life scores across all SF-36 domains; the study reported that "increasing severity of hot flushes was significantly associated with lower HRQoL scores across all SF-36 domains." (hot flashes & HRQoL study, PubMed)

That matters because perimenopause symptoms are not happening "in your head" or in isolation. A night sweat can fragment sleep; poor sleep can make pain louder, anxiety sharper, and memory less reliable the next day. Hot flashes can also come with a racing heartbeat, sweating, dizziness, and sudden awakenings, so your nervous system may feel activated even when you're trying to rest. (Johns Hopkins Medicine)

Treatment is not a moral test, and it does not mean you have to start medication. It means the symptom is worth naming, tracking, and matching to the right level of support — from trigger management and sleep changes to prescription options when symptoms interfere with daily life. Johns Hopkins notes that perimenopause symptoms do not need treatment unless they are bothersome; Cleveland Clinic similarly recommends talking with a healthcare provider when hot flashes disrupt daily life. (Johns Hopkins Medicine)

So the practical question is not "Can I endure this?" It is: "What is this costing me — sleep, work, relationships, training, mood, confidence — and what would make my body easier to live in?" That is a valid reason to treat.

How we made it

Made with AI tools, then edited, fact-checked, and medically reviewed by the Welltory team.

Trust

Data analysis by Jane Smorodnikova — the founder and CEO of Welltory. A recognized tech leader with two Master's degrees and experience at MIT, she has scaled Welltory to over 17 million users.

Written by Kseniia Iaroslavtseva — COO at Welltory. She reviews scientific research and turns it into structured, readable insights.

Reviewed by Anna Elitzur — Medical Advisor & Mental Health Expert. Anna holds her medical degree and reviews health content across topics for medical accuracy and consistency with current clinical guidelines and research.

Medical note: This is general education, not medical advice. Do not start, stop, or change any medication, hormone therapy, or supplement based on this article. Whether a treatment is appropriate — and its dose — must be individualized by a qualified clinician.

```json { "@context": "https://schema.org", "@type": "MedicalWebPage", "lastReviewed": "2026-07-04", "contributor": { "@type": "Person", "@id": "https://welltory.com/authors/jane-smorodnikova/#person", "name": "Jane Smorodnikova", "jobTitle": "Founder and CEO at Welltory", "affiliation": { "@type": "Organization", "name": "Welltory" }, "url": "https://welltory.com/authors/jane-smorodnikova/", "description": "The founder and CEO of Welltory. A recognized tech leader with two Master's degrees and experience at MIT, she has scaled Welltory to over 17 million users.", "knowsAbout": [ "Health data analysis", "Digital health", "Heart rate variability" ] }, "author": { "@type": "Person", "@id": "https://welltory.com/authors/kseniia-iaroslavtseva/#person", "name": "Kseniia Iaroslavtseva", "jobTitle": "Chief Operating Officer at Welltory", "affiliation": { "@type": "Organization", "name": "Welltory" }, "url": "https://welltory.com/authors/kseniia-iaroslavtseva/", "description": "Reviews scientific research and turns it into structured, readable insights.", "knowsAbout": [ "Research synthesis", "Health science communication", "Evidence-based content" ] }, "reviewedBy": { "@type": "Person", "@id": "https://welltory.com/authors/anna-elitzur/#person", "name": "Anna Elitzur", "jobTitle": "Medical Advisor & Mental Health Expert", "affiliation": { "@type": "Organization", "name": "Welltory" }, "url": "https://welltory.com/authors/anna-elitzur/", "description": "Holds her medical degree and reviews health content across topics for medical accuracy and consistency with current clinical guidelines and research.", "hasCredential": { "@type": "EducationalOccupationalCredential", "credentialCategory": "Medical Degree" }, "knowsAbout": [ "Behavioral health", "Mental health", "Chronic conditions", "Cardiovascular health", "Sleep", "Stress physiology" ] } } ```

Discounts for blog readers: up to 36% off

See what affects your energy, stress, sleep, and daily state with Welltory

Explore your data